KBTBD6 Inhibitors

Kelch Repeat and BTB Domain-Containing Protein 6 (KBTBD6) inhibitors listed here target cellular processes and pathways associated with ubiquitination and RAC1 signaling, indirectly influencing KBTBD6's function. MLN 4924, by inhibiting NEDD8-activating enzyme, could impact CUL3-based ubiquitin ligase activities, including those involving KBTBD6. Proteasome inhibitors like Bortezomib and MG-132 [Z-Leu- Leu-Leu-CHO] are relevant due to their role in affecting proteasomal degradation processes related to KBTBD6's function. Compounds such as NSC 23766 Trihydrochloride, EHop-016, and ZCL278 that inhibit Rac1-GEF interaction or Rac1 activation, could influence pathways regulated by KBTBD6. Rac1 inhibitors directly target Rac1, impacting KBTBD6-modulated pathways.

MEK inhibitor PD 98059 and PI3K inhibitor LY 294002 are included for their ability to affect downstream signaling pathways associated with KBTBD6's function. GSK 269962, a Rho kinase inhibitor, might influence cytoskeletal organization and cell migration processes where KBTBD6 is involved. Dasatinib, a broad tyrosine kinase inhibitor, could influence signaling processes mediated by KBTBD6. In summary, the approach to targeting KBTBD6 involves modulating key pathways in ubiquitination, RAC1 signaling, and related cellular processes such as cytoskeleton organization, cell migration, and proliferation. The inhibitors listed, by affecting these pathways, offer routes to influence KBTBD6's activity, considering its role in the regulation of RAC1 signal transduction and other biological processes.